Following up on our last Affimed post, Affimed hosted their call last week to discuss details of AFM13+NK cells from MD Anderson. Overall, the data was very promising as it showed dose response and early durability. AFMD stock however traded down 8%, with XBI down over 4%.
Before diving into the data, let’s recap the process and patient demographics.
Proc…